Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BioNTech, which acquired BNT327 in an $800 million acquisition of China-based biotech Biotheus late last year, has advanced the drug into Phase 3 trials in both small cell and non-small cell lung ...

Investing.com -- Shares in BioNTech (NASDAQ: BNTX) soared sharply Monday after Bristol-Myers Squibb Company (NYSE: BMY) agreed to pay $1.5 billion upfront to collaborate with the German biotech firm ...

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential ...

With the acquisition, BNTX will gain full global rights to BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A, which is currently being developed in mid-to-late-stage ...

BioNTech SE has signed a definitive agreement to acquire Biotheus, a clinical-stage biotech company, with the goal of enhancing its oncology strategy. The acquisition includes access to BNT327/PM8002, ...

BNT327, BioNTech’ s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BioNTech shares were up 14.8% as of 07:35 GMT. Under the agreement, Bristol Myers will jointly develop and commercialize BNT327, a bispecific antibody being studied for a range of solid tumors.

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...